



## **ANNOUNCEMENT NO. 218**

28 January 2022

### **Revenue and EBITDA guidance raised**

In the first half of the financial year 2021/22, ChemoMetec continued its positive development, and sales and order intake developed significantly better than expected.

Based on the above, ChemoMetec now expects revenue in the financial year 2021/22 in the DKK 385-395 million range, up from DKK 370-380 million, and EBITDA is expected to be in DKK 195-200 million range, up from DKK 175-180 million.

### **For further information**

Steen Søndergaard, CEO, ChemoMetec A/S

Phone: (+45) 4813 1020

### **About ChemoMetec A/S**

*ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec's instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec's customers include some of the world's leading pharmaceutical companies such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.*

*ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For more information, go to [www.chemometec.com](http://www.chemometec.com).*